Home › All Companies › ATRA › Annual Report

Atara Biotherapeutics, Inc. (ATRA) — Annual Report

AI-Powered SEC Filing Analysis

← All ATRA filings
Latest Annual Report Filed: 2026-03-16

Key Insights

  • Atara Biotherapeutics' research and development expenses increased significantly in 2025, indicating a focus on advancing its pipeline of novel therapies.
  • The company reported an increase in commercial revenue in 2024, suggesting progress in commercializing its products.
  • Atara has been active in raising additional capital through various financing activities, including public offerings and at-the-market offerings, to support its ongoing operations and development efforts.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Atara Biotherapeutics, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.